Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers
暂无分享,去创建一个
Patrick W. Lee | K. McLure | C. Nicholls | Michael A Shields | Kevin G. McLure | Patrick W. K. Lee | Chris D. Nicholls | Michael A. Shields | Patrick Lee
[1] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[2] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[3] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[4] A. Levine,et al. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. , 1990, Virology.
[5] W. Cavenee,et al. Mechanisms of p53 loss in human sarcomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Milner,et al. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.
[7] J. Marks,et al. Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.
[8] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[9] C. Theillet,et al. p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.
[10] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[11] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[12] E. Shaulian,et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.
[13] P. Friedman,et al. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.
[14] A. Chumakov,et al. Analysis of p53 transactivation through high-affinity binding sites. , 1993, Oncogene.
[15] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[16] L. Donehower,et al. Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice , 1993, Nature Genetics.
[17] D. Malkin,et al. p53 and the Li-Fraumeni syndrome. , 1993, Cancer genetics and cytogenetics.
[18] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[19] A. Gronenborn,et al. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.
[20] A. Chumakov,et al. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. , 1994, Oncogene.
[21] S. Friend,et al. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. , 1994, Cancer research.
[22] A. Chumakov,et al. Mutant p53 proteins behave in a dominant, negative fashion in vivo. , 1994, Anticancer research.
[23] C. Arrowsmith,et al. Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.
[24] D. Beach,et al. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.
[25] S. Velasco-Miguel,et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.
[26] G. Marius Clore,et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.
[27] T. Halazonetis,et al. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. , 1995, The EMBO journal.
[28] J. Milner,et al. Specific DNA binding by different classes of human p53 mutants. , 1995, Oncogene.
[29] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[30] N. Pavletich,et al. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.
[31] M. Oren,et al. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.
[32] Thierry Soussi,et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..
[33] J. Heighway,et al. No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. , 1996, British Journal of Cancer.
[34] M. Coffey,et al. Co‐translational trimerization of the reovirus cell attachment protein. , 1996, The EMBO journal.
[35] T. Halazonetis,et al. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. , 1996, Cancer research.
[36] H. Sakamoto,et al. Effect of Phosphorylation on Tetramerization of the Tumor Suppressor Protein p53 , 1997, Journal of protein chemistry.
[37] M. Grütter,et al. In vitro structure-function analysis of the beta-strand 326-333 of human p53. , 1997, Journal of molecular biology.
[38] K. Kinzler,et al. 14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .
[39] H. Sakamoto,et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. , 1997, Biochemistry.
[40] D. Evans,et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene , 1997, Oncogene.
[41] P. Chène. In vitro analysis of the dominant negative effect of p53 mutants. , 1998, Journal of molecular biology.
[42] K. McLure,et al. How p53 binds DNA as a tetramer , 1998, The EMBO journal.
[43] D. Pinkel,et al. Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.
[44] D. Israeli,et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.
[45] A. Hengstermann,et al. Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1 , 1999, The EMBO journal.
[46] K. Roemer. Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators , 1999, Biological chemistry.
[47] D. Troyer,et al. Disruption of functions of wild-type p53 by hetero-oligomerization. , 1999, International journal of oncology.
[48] Alan R. Fersht,et al. Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53 , 1999, Nature Structural Biology.
[49] R. Hay,et al. SUMO‐1 modification activates the transcriptional response of p53 , 1999, The EMBO journal.
[50] G. Wahl,et al. A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.
[51] J. Manfredi,et al. One Mechanism for Cell Type-specific Regulation of thebax Promoter by the Tumor Suppressor p53 Is Dictated by the p53 Response Element* , 1999, The Journal of Biological Chemistry.
[52] P. Chène,et al. p53 mutants without a functional tetramerisation domain are not oncogenic. , 1999, Journal of molecular biology.
[53] K. McLure,et al. p53 DNA binding can be modulated by factors that alter the conformational equilibrium , 1999, The EMBO journal.
[54] M. Ljungman. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. , 2000, Neoplasia.
[55] C. Maki,et al. The MDM2 RING-finger domain is required to promote p53 nuclear export , 2000, Nature Cell Biology.
[56] Yunping Lin,et al. Pidd, a new death-domain–containing protein, is induced by p53 and promotes apoptosis , 2000, Nature Genetics.
[57] M. Blagosklonny,et al. p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] E. Stanbridge,et al. p53 Mutants Have Selective Dominant-Negative Effects on Apoptosis but Not Growth Arrest in Human Cancer Cell Lines , 2000, Molecular and Cellular Biology.
[59] K. Tsai,et al. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 , 2000, Nature Cell Biology.
[60] T. Hara,et al. Form of human p53 protein during nuclear transport in Xenopus laevis embryos. , 2000, Experimental cell research.
[61] M. Kulesz-Martin,et al. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. , 2001, Carcinogenesis.